{"id":4529,"date":"2015-06-29T12:49:44","date_gmt":"2015-06-29T12:49:44","guid":{"rendered":"http:\/\/canyonhealth.net\/blog\/2015\/06\/29\/vitae-boehringer-diabetes-drug-fails-as-add-on-therapy-in-trial\/"},"modified":"2015-06-29T12:49:44","modified_gmt":"2015-06-29T12:49:44","slug":"vitae-boehringer-diabetes-drug-fails-as-add-on-therapy-in-trial","status":"publish","type":"post","link":"https:\/\/stuff2host.com\/index.php\/2015\/06\/29\/vitae-boehringer-diabetes-drug-fails-as-add-on-therapy-in-trial\/","title":{"rendered":"Vitae-Boehringer diabetes drug fails as add-on therapy in trial"},"content":{"rendered":"<p>(Reuters) &#8211; Vitae Pharmaceuticals Inc said its drug to treat type 2 diabetes in overweight patients did not meet its main goal in a mid-stage study testing it as an add-on therapy. The drug, being co-developed with German drugmaker Boehringer Ingelheim, was tested as an add-on therapy to metformin, a commonly prescribed diabetes drug. The blood sugar levels of patients taking the drug as an add-on therapy did not reduce significantly, Vitae said in a statement on Monday.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(Reuters) &#8211; Vitae Pharmaceuticals Inc said its drug to treat type 2 diabetes in overweight patients did not meet its main goal in a mid-stage study testing it as an add-on therapy. The drug, being co-developed with German drugmaker Boehringer Ingelheim, was tested as an add-on therapy to metformin, a commonly prescribed diabetes drug. The [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[23,33,67,80,81,82,85],"class_list":["post-4529","post","type-post","status-publish","format-standard","hentry","category-weight-management","tag-diet","tag-hcg","tag-phentermine","tag-weight","tag-weight-clinic","tag-weight-loss","tag-weight-managenemt"],"aioseo_notices":[],"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/stuff2host.com\/index.php\/wp-json\/wp\/v2\/posts\/4529","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stuff2host.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stuff2host.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stuff2host.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stuff2host.com\/index.php\/wp-json\/wp\/v2\/comments?post=4529"}],"version-history":[{"count":0,"href":"https:\/\/stuff2host.com\/index.php\/wp-json\/wp\/v2\/posts\/4529\/revisions"}],"wp:attachment":[{"href":"https:\/\/stuff2host.com\/index.php\/wp-json\/wp\/v2\/media?parent=4529"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stuff2host.com\/index.php\/wp-json\/wp\/v2\/categories?post=4529"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stuff2host.com\/index.php\/wp-json\/wp\/v2\/tags?post=4529"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}